New drug tested in race against recurrent brain cancer

NCT ID NCT06552260

Summary

This early study is testing whether the drug troriluzole can help control recurrent glioblastoma, an aggressive brain cancer. About 27 adults whose cancer has returned will receive the drug either before and after standard tumor-removal surgery, or only after surgery, to see if it affects tumor activity. The main goal is to understand how the drug impacts brain cell activity during surgery and its safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital Cancer Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.